Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental Endocarditis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
GAR-936, a novel glycylcycline, was investigated with a rat model of experimental endocarditis. It was compared with vancomycin against both vancomycin-susceptible and -resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus . GAR-936 exhibited the lowest MICs (≤0.12 μg/ml) in vitro against each of the isolates tested. Endocarditis was established by placement of a catheter across the aortic valve, followed by intravenous injection of 10 6 CFU of bacteria 48 h later. Treatment with GAR-936 or vancomycin was initiated 24 to 36 h after bacterial infection and administered subcutaneously twice a day for 3 days at ascending doses. GAR-936 reduced bacterial vegetation titers by >2 log 10 CFU, compared to those in untreated controls, for both vancomycin-susceptible and -resistant (VanA and VanB) E. faecalis strains and >4 log 10 CFU for a methicillin-resistant S. aureus isolate. The glycylcycline was more efficacious at a lower administered dose in the rat model of endocarditis than was vancomycin. The efficacy of GAR-936 in this model was apparently not enhanced by a factor in rat serum, as was observed for vancomycin with a time-kill curve. The results of this study demonstrate the therapeutic potential of GAR-936 for the treatment of enterococcal and staphylococcal infections and warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fantin, B., Leclercq, R., Ottaviani, M., Vallois, J. M., Maziere, B., Duval, J., Pocidalo, J. J., & Carbon, C. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.3.432 · Cited by 44
Cited by
Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines
Agwuh, K. N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl224 · Cited by 806
Sortases and the Art of Anchoring Proteins to the Envelopes of Gram-Positive Bacteria
Marraffini, L. A., DeDent, A. C., & Schneewind, O. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.70.1.192-221.2006 · Cited by 686
The Glycylcyclines: A Comparative Review with the Tetracyclines
Zhanel, G. G., Homenuik, K., Nichol, K., Noreddin, A., Vercaigne, L., Embil, J., Gin, A., Karlowsky, J. A., & Hoban, D. J. (2004) · Drugs · doi:10.2165/00003495-200464010-00005 · Cited by 306
Pankey, G. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki248 · Cited by 301
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Metadata
- Authors
- Murphy, T. M., Deitz, J. M., Petersen, P. J., Mikels, S. M., & Weiss, W. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2000-11
- Volume
- 44
- Issue
- 11
- Pages
- 3022-3027
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2168550647
- Cited by
- 80
- References
- 1
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental Endocarditis. https://app.cochat.ai/papers/10.1128/aac.44.11.3022-3027.2000
- The paper
- Murphy, T. M., Deitz, J. M., Petersen, P. J., Mikels, S. M., & Weiss, W. J. (2000). Therapeutic Efficacy of GAR-936, a Novel Glycylcycline, in a Rat Model of Experimental Endocarditis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.44.11.3022-3027.2000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.